Navigation Links
Neuromonics Signs Reselling Agreement with Elite Hearing Network
Date:8/13/2014

Westminster, CO (PRWEB) August 13, 2014

Neuromonics, Inc., manufacturer and distributor of clinically proven tinnitus treatment devices, has signed a new reseller agreement with Elite Hearing Network.

Elite will offer special pricing, marketing, training and other support for all Neuromonics products to its network of 800 clinicians through the agreement. Elite provides business support services to independent hearing care practices throughout the United States. The agreement extends a relationship Neuromonics has had with Elite since 2012, according to Eula Adams, CEO of Neuromonics.

“The new agreement further builds on a strong relationship between Elite and Neuromonics,” says Adams. “Elite Hearing is a critical link to Neuromonics’ ability to deliver the miracle of tinnitus relief to tinnitus sufferers.”

Neuromonics manufactures and distributes clinically proven, FDA-cleared medical devices to treat tinnitus, the condition often described as buzzing, ringing, hissing, humming, roaring, whistling or "ringing in the ears” that someone hears in the absence of any external sound. Globally, tinnitus affects an estimated 10-15 percent of the population. In the United States alone, more than 50 million people suffer from the condition, according to the American Tinnitus Association. Usually brought on by exposure to loud noise, tinnitus is especially significant in the military, with more than 34 percent of returning veterans from Iraq and Afghanistan suffering from the condition.

Neuromonics products use calming, relaxing music embedded with a neural stimulus that interacts with the tinnitus perception, explains Adams. The music engages the auditory pathways to promote neural plastic changes. Over time, these changes help the brain to filter out the tinnitus perception, reducing tinnitus disturbance and providing long-term relief from symptoms. The compact devices are simple to use, function much like familiar consumer music players, and fit easily into patients’ lifestyles.

Neuromonics, Inc. (http://www.neuromonics.com)
Based in Westminster, Colo., Neuromonics, Inc., manufactures and distributes clinically proven, FDA-cleared medical devices to treat tinnitus. The patented and clinically proven Oasis, working the Neuromonics Tinnitus Treatment, provides long-term treatment and significant relief for those with severe tinnitus. The Haven, with the ability to program and individualize hearing profiles, is a management tool offering situational relief for tinnitus symptoms. The Sanctuary, also a management tool, works with pre-programmed profiles for on-demand relief.

With research and development beginning in the early 1990s, Neuromonics has helped thousands of tinnitus sufferers improve their quality of life and overcome the daily life challenges associated with tinnitus. More than 400 licensed, trained audiologists across four continents administer the Neuromonics Tinnitus Treatment. Neuromonics news includes segments on national media including “The Doctors” and CNN.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12087827.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neuromonics Names Eula Adams CEO
2. Neuromonics Unveils New Device to Relieve Mild, Moderate Tinnitus at Audiology NOW!
3. Know the Risks and Warning Signs of Brain Aneurysms--What You Need to Know Right Now is Available Through the Brain Aneurysm Foundation
4. 5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls
5. Rewired mice show signs of longer lives with fewer age-related illnesses
6. Dallas-Based Park Cities Pet Sitter Stresses the Importance of Mindful Communication in This Month’s Staff Meetings, In Addition to Teaching the Signs of Burnout
7. Healthy Habits May Slow Cellular Signs of Aging, Study Finds
8. New radiological signs of gastric lap band slippage identified
9. Research led by Temples chair of dermatology: Pain and itch may be signs of skin cancer
10. Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow
11. New Designs of Sweet 15 Quinceanera Dresses Added to Magicquinceaneradresses.com’s Product Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: